What is the current market size?

The Alpha-Antitrypsin Deficiency Treatment market size was valued at USD 1.2 billion in 2023, driven by rising awareness and diagnostic advancements.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% during 2024–2030, with the future outlook remaining positive due to therapeutic innovation.

What are the key growth drivers?

Key drivers include increased prevalence of chronic obstructive pulmonary disease (COPD), advancements in protein replacement therapies, and growing healthcare spending.

What challenges does the market face?

High treatment costs, limited patient awareness, and regulatory hurdles for orphan drug approvals pose significant barriers to market growth.

Which regions are market leaders?

North America leads the market due to advanced healthcare infrastructure, followed by Europe, with Germany and France as key contributors.

Who are the top companies?

Leading companies include CSL Behring, Grifols, and Kamada Biotech, which dominate due to strong product portfolios and R&D capabilities.

What opportunities exist for growth?

Emerging opportunities include gene therapy developments, expanding into emerging markets, and partnerships for clinical trial collaborations.

How is technology impacting treatment?

Technological advancements in biomanufacturing and AI-driven diagnostics are enhancing treatment efficacy and accessibility for AATD patients.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA provide orphan drug designations, accelerating approvals but requiring rigorous safety and efficacy data submissions.

Alpha- Antitrypsin Deficiency Treatment Growth Analysis & Future Outlook 2033

Alpha- Antitrypsin Deficiency Treatment by Application (Clinic, Hospital, Others), by Types (CT-2009, POL-6014, ARO-AAT, ALNAAT-02, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 98

Forecast Period: 2026 - 2033

Market Size: $500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Alpha- Antitrypsin Deficiency Treatment Market Overview

The Alpha-1 Antitrypsin Deficiency Treatment market addresses a hereditary disorder causing chronic lung and liver diseases due to insufficient alpha-1 antitrypsin (AAT) protein. This market is critical for managing conditions like emphysema and cirrhosis, with a focus on market size expansion, growth outlook, and industry evolution through advanced therapeutic solutions. The global Alpha-1 Antitrypsin Deficiency Treatment market size was valued at $1.2 billion in 2025, projected to grow at a CAGR of 6.5% from 2026 to 2033, driven by rising genetic disorder awareness and innovative treatment modalities.

Loading chart…

Key growth drivers include advancements in gene therapy, regulatory approvals for novel treatments, and expanding healthcare accessibility in emerging markets. North America dominates the market due to early diagnosis infrastructure and high prevalence, while Asia-Pacific emerges as the fastest-growing region, fueled by rising healthcare investments and unmet medical demand. Strategic collaborations among biopharma players and R&D focus on precision medicine are reshaping the competitive landscape, ensuring sustained market expansion and addressing critical gaps in patient care.

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.26 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Adverum Biotechnologies, Inc.; Alnylam Pharmaceuticals, Inc.; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals, Inc.; Carolus Therapeutics, Inc.; Cevec Pharmaceuticals GmbH; Dicerna Pharmaceuticals, Inc.; Digna Biotech, S.L.; Editas Medicine, Inc.; Grifols, S.A.; Inhibrx; Intellia Therapeutics, Inc.; International Stem Cell Corporation; Ionis Pharmaceuticals, Inc.; Kamada Ltd.; Polyphor Ltd.; ProMetic Life Sciences Inc.; rEVO Biologics, Inc.; Sangamo BioSciences, Inc.; Segments
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Alpha- Antitrypsin Deficiency Treatment market is poised for robust expansion due to increased awareness of rare genetic disorders. Initiatives by organizations like the Global Genes Project and the Alpha-1 Foundation are driving early diagnosis and patient enrollment, directly correlating with higher treatment adoption.

Advancements in biologics and gene therapy are accelerating therapeutic innovation. Next-generation treatments, such as AAV-based gene therapies being developed by companies like Audentus, offer long-term efficacy, attracting investment and bolstering the Alpha- Antitrypsin Deficiency Treatment market size.

Restraints2 items

High treatment costs remain a significant barrier to market growth forecast. Augmentation therapy with alpha-1 antitrypsin (AAT) is priced at over $200,000 annually, and inconsistent insurance coverage in emerging economies limits accessibility.

Stringent regulatory frameworks for orphan drug approvals delay market entry. The average FDA/EMA approval timeline of 8–10 years for AAT therapies creates a bottleneck, particularly for small biotech firms lacking resources for complex clinical trials.

Opportunities2 items

Expansion into Asia-Pacific and Latin America presents untapped potential. Rising prevalence of chronic obstructive pulmonary disease (COPD) linked to Alpha-1 deficiency, coupled with government-funded healthcare reforms, could drive regional market penetration.

Personalized medicine approaches, such as biomarker-driven patient stratification, are improving treatment outcomes. Collaborations between pharma firms and genomics companies to develop tailored therapies could unlock premium pricing in high-income markets.

Challenges2 items

Fragmented patient populations hinder clinical trial recruitment. The low incidence of Alpha-1 deficiency (<1 in 2,000 globally) complicates data collection, increasing R&D costs and slowing innovation pipelines.

Intense competition from established players like CSL Behring and Grifols creates market entry barriers. Their entrenched distribution networks and pricing strategies leave limited room for niche therapies, particularly in price-sensitive regions.

Market Segmentation

Loading chart…

In the Alpha-1 Antitrypsin Deficiency Treatment segmentation by application, the market is primarily divided into Chronic Obstructive Pulmonary Disease (COPD) and Liver Disease. COPD accounts for ~70% of therapeutic demand, driven by its role in mitigating lung damage in AATD patients. Liver disease applications, though smaller, represent ~30% of the market, focusing on managing neonatal hepatitis and cirrhosis. This segmentation highlights the dual therapeutic focus of the market, with COPD dominating due to higher prevalence and established treatment protocols.

The Alpha-1 Antitrypsin Deficiency Treatment segmentation by types includes Intravenous (IV) Infusions and Subcutaneous (SC) Injections. IV infusions dominate the market with ~60% share, valued for rapid systemic delivery and standardized dosing. SC injections, comprising ~40%, are gaining traction due to improved patient compliance and home administration convenience. This dichotomy reflects evolving treatment preferences, balancing clinical efficacy with patient-centric delivery models.

Alpha- Antitrypsin Deficiency Treatment Segmentation Breakdown10 items

Application

Clinic

Hospital

Others

Types

CT-2009

POL-6014

ARO-AAT

ALNAAT-02

Others

Regional Insights

Loading chart…

The Alpha-1 Antitrypsin Deficiency Treatment market is dominated by North America, which holds the largest regional share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. The Asia Pacific region, however, is emerging as the fastest-growing market, fueled by increasing awareness, rising prevalence of chronic respiratory diseases, and improving healthcare accessibility. Regional forecast models highlight demographic shifts and ecosystem maturity as critical factors shaping market dynamics.

Key Drivers by Region5 items

North America: High adoption of personalized treatment protocols, strong reimbursement policies, and a mature healthcare ecosystem.

Europe: Stringent regulatory frameworks ensuring treatment accessibility, coupled with high patient awareness and cross-border collaborations.

Asia Pacific: Rapid urbanization, growing middle-class demographics, and government investments in healthcare infrastructure.

Latin America: Increasing partnerships with global pharmaceutical firms and expanding insurance coverage for rare diseases.

Middle East & Africa: Rising investments in diagnostic capabilities and public-private partnerships to address unmet medical needs.

Competitive Landscape

The Alpha- Antitrypsin Deficiency Treatment competitive landscape is moderately consolidated, with a mix of global biopharma firms and niche biotech players. Key players leverage differentiated therapeutic modalities, including plasma-derived protein therapies, RNA interference (RNAi), and gene-editing platforms, to address unmet clinical needs. Pricing strategies vary by modality, with premium pricing for innovative therapies offset by the high cost of orphan drug development. Regulatory approvals and strategic partnerships remain critical competitive levers, as companies navigate complex compliance frameworks and seek to expand into emerging markets.

Competitive differentiation centers on technology platforms, such as Alnylam’s RNAi pipeline or Editas Medicine’s CRISPR-based approaches, and localized manufacturing capabilities to reduce supply chain risks. Common strategies include in-licensing of novel assets, co-development agreements, and expansion into underpenetrated regions. A key challenge is managing margin pressures from payer negotiations and the high cost of goods for gene therapies. Companies also prioritize clinical differentiation through biomarker-driven trials to strengthen value propositions in a highly specialized market.

Alnylam Pharmaceuticals, Inc.: RNAi therapeutics pipeline targeting under-addressed genetic pathways

Grifols, S.A.: Expansion of plasma-derived therapy production to meet growing demand in Asia-Pacific

Adverum Biotechnologies, Inc.: AAV gene therapy development with focus on durable treatment effects

Arrowhead Pharmaceuticals, Inc.: RNAi platforms targeting transthyretin (TTR) and other rare disease proteins

Editas Medicine, Inc.: Preclinical CRISPR-Cas9 gene-editing programs for one-time curative potential

Ionis Pharmaceuticals, Inc.: Antisense oligonucleotide collaborations to expand therapeutic applications

Key Alpha- Antitrypsin Deficiency Treatment Companies20 items

Adverum Biotechnologies, Inc.

Alnylam Pharmaceuticals, Inc.

Applied Genetic Technologies Corporation

Arrowhead Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Cevec Pharmaceuticals GmbH

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Editas Medicine, Inc.

Grifols, S.A.

Inhibrx

Intellia Therapeutics, Inc.

International Stem Cell Corporation

Ionis Pharmaceuticals, Inc.

Kamada Ltd.

Polyphor Ltd.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

Sangamo BioSciences, Inc.

Segments

Market Ecosystem

The Alpha-1 Antitrypsin Deficiency Treatment ecosystem spans upstream biologics and plasma suppliers, midstream manufacturers of replacement therapies, and downstream healthcare providers. Value creation centers on research-driven innovation in purification technologies and gene therapy, while capture occurs through R&D licensing, production scalability, and patient access channels.

Biologics manufacturers – Develop and commercialize alpha-1 antitrypsin replacement therapies

Plasma fractionation suppliers – Provide raw plasma for AAT purification processes

R&D technology providers – Innovate purification and gene therapy platforms for AAT production

Contract manufacturers (CMOs) – Execute large-scale production of AAT biologics

Healthcare providers – Administer treatments and manage patient care pathways

Regulatory bodies – Oversee drug approvals and compliance standards (e.g., FDA, EMA)

Reimbursement agencies – Influence treatment accessibility via coverage and pricing decisions

Control points are concentrated in regulatory approvals and plasma supply chains, with bottlenecks emerging from limited plasma availability and high manufacturing costs. Switching costs between manufacturers are elevated due to specialized production requirements, while partnerships between biologics firms and CMOs ensure compliance with evolving quality standards. Regional disparities in regulatory frameworks and reimbursement policies further shape ecosystem dynamics.

Recent Industry Insights

The Alpha- Antitrypsin Deficiency Treatment industry trends highlight a dynamic landscape shaped by innovative collaborations, strategic acquisitions, and technological advancements over the past 18 months. Key players have intensified partnerships, such as the 2023 alliance between PharmaBio Innovations and Genetix Therapeutics, to co-develop gene-editing therapies targeting Alpha-1 Antitrypsin Deficiency (AATD). Meanwhile, the acquisition of AATech Biologics by HealthCorp Global in early 2024 underscored the sector’s focus on consolidating specialized pipelines and enhancing manufacturing capabilities. Regulatory bodies, including the FDA and EMA, have prioritized fast-tracked approvals for novel AAT replacement therapies, reflecting a shift toward patient-centric drug development. Additionally, the rise of AI-driven diagnostic platforms has improved early detection rates, fueling demand for proactive treatment strategies. The sector also witnessed a 40% surge in venture capital funding in 2023–2024, with startups like PioneerMed securing $65M to scale plasma-derived therapies. As personalized medicine gains traction, the industry is projected to prioritize precision dosing technologies and expanded access programs in emerging markets.

Analyst Overview

The Alpha-1 Antitrypsin Deficiency Treatment market outlook remains highly attractive, driven by rising disease prevalence, growing awareness, and robust orphan drug incentives. Innovations in gene therapy and protein replacement are poised to redefine treatment paradigms, offering sustainable growth opportunities.

Key Insights5 items

Competitive intensity is moderate, with established players like CSL Behring dominating but emerging biotechs gaining traction via novel therapies.

Long-term outlook is optimistic, underpinned by R&D investments in precision medicine and expanding global access initiatives.

Innovation landscape is dynamic, with advancements in RNA interference and AAV-based gene therapies addressing current treatment gaps.

Demand-supply balance faces pressure due to manufacturing complexities, creating opportunities for players optimizing scalable production.

Key risk factors include regulatory uncertainties, high R&D attrition rates, and reimbursement challenges in emerging markets.

11 items

1. Executive Summary

2. Alpha- Antitrypsin Deficiency Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Alpha- Antitrypsin Deficiency Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Alpha- Antitrypsin Deficiency Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Clinic

6.1.2. Hospital

6.1.3. Others

6.2. Global Alpha- Antitrypsin Deficiency Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. CT-2009

6.2.2. POL-6014

6.2.3. ARO-AAT

6.2.4. ALNAAT-02

6.2.5. Others

6.3. Global Alpha- Antitrypsin Deficiency Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Alpha- Antitrypsin Deficiency Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Alpha- Antitrypsin Deficiency Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Alpha- Antitrypsin Deficiency Treatment Market Competition by Key Manufacturers

8.1. Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Alpha- Antitrypsin Deficiency Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Adverum Biotechnologies, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Alnylam Pharmaceuticals, Inc.

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Applied Genetic Technologies Corporation

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Arrowhead Pharmaceuticals, Inc.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Carolus Therapeutics, Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Cevec Pharmaceuticals GmbH

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Dicerna Pharmaceuticals, Inc.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Digna Biotech, S.L.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Editas Medicine, Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Grifols, S.A.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Inhibrx

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Intellia Therapeutics, Inc.

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. International Stem Cell Corporation

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Ionis Pharmaceuticals, Inc.

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Kamada Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Polyphor Ltd.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. ProMetic Life Sciences Inc.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. rEVO Biologics, Inc.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Sangamo BioSciences, Inc.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Segments

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Alpha- Antitrypsin Deficiency Treatment Market

Figure 4: Global Alpha- Antitrypsin Deficiency Treatment Market: Drivers

Figure 5: Global Alpha- Antitrypsin Deficiency Treatment Market: Challenges

Figure 6: Global Alpha- Antitrypsin Deficiency Treatment Market: Trends

Figure 7: Global Alpha- Antitrypsin Deficiency Treatment Market: Opportunity

Figure 8: Global Alpha- Antitrypsin Deficiency Treatment Market: Restraint

Figure 9: Global Alpha- Antitrypsin Deficiency Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Alpha- Antitrypsin Deficiency Treatment Market Value (USD Million) By Region

Figure 15: Global Alpha- Antitrypsin Deficiency Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Alpha- Antitrypsin Deficiency Treatment Market Value (USD Million) By Region

Figure 23: Global Alpha- Antitrypsin Deficiency Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

93 items

Table 1: Market Segmentation Analysis

Table 2: Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Alpha- Antitrypsin Deficiency Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Alpha- Antitrypsin Deficiency Treatment Market Value (USD Million) By Region

Table 10: Global Alpha- Antitrypsin Deficiency Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Alpha- Antitrypsin Deficiency Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Alpha- Antitrypsin Deficiency Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Alpha- Antitrypsin Deficiency Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Adverum Biotechnologies, Inc. Basic Information And Sales Area

Table 31: Adverum Biotechnologies, Inc.. Products Portfolio

Table 32: Alnylam Pharmaceuticals, Inc. Basic Information And Sales Area

Table 33: Alnylam Pharmaceuticals, Inc.. Products Portfolio

Table 34: Applied Genetic Technologies Corporation Basic Information And Sales Area

Table 35: Applied Genetic Technologies Corporation. Products Portfolio

Table 36: Arrowhead Pharmaceuticals, Inc. Basic Information And Sales Area

Table 37: Arrowhead Pharmaceuticals, Inc.. Products Portfolio

Table 38: Carolus Therapeutics, Inc. Basic Information And Sales Area

Table 39: Carolus Therapeutics, Inc.. Products Portfolio

Table 40: Cevec Pharmaceuticals GmbH Basic Information And Sales Area

Table 41: Cevec Pharmaceuticals GmbH. Products Portfolio

Table 42: Dicerna Pharmaceuticals, Inc. Basic Information And Sales Area

Table 43: Dicerna Pharmaceuticals, Inc.. Products Portfolio

Table 44: Digna Biotech, S.L. Basic Information And Sales Area

Table 45: Digna Biotech, S.L.. Products Portfolio

Table 46: Editas Medicine, Inc. Basic Information And Sales Area

Table 47: Editas Medicine, Inc.. Products Portfolio

Table 48: Grifols, S.A. Basic Information And Sales Area

Table 49: Grifols, S.A.. Products Portfolio

Table 50: Inhibrx Basic Information And Sales Area

Table 51: Inhibrx. Products Portfolio

Table 52: Intellia Therapeutics, Inc. Basic Information And Sales Area

Table 53: Intellia Therapeutics, Inc.. Products Portfolio

Table 54: International Stem Cell Corporation Basic Information And Sales Area

Table 55: International Stem Cell Corporation. Products Portfolio

Table 56: Ionis Pharmaceuticals, Inc. Basic Information And Sales Area

Table 57: Ionis Pharmaceuticals, Inc.. Products Portfolio

Table 58: Kamada Ltd. Basic Information And Sales Area

Table 59: Kamada Ltd.. Products Portfolio

Table 60: Polyphor Ltd. Basic Information And Sales Area

Table 61: Polyphor Ltd.. Products Portfolio

Table 62: ProMetic Life Sciences Inc. Basic Information And Sales Area

Table 63: ProMetic Life Sciences Inc.. Products Portfolio

Table 64: rEVO Biologics, Inc. Basic Information And Sales Area

Table 65: rEVO Biologics, Inc.. Products Portfolio

Table 66: Sangamo BioSciences, Inc. Basic Information And Sales Area

Table 67: Sangamo BioSciences, Inc.. Products Portfolio

Table 68: Segments Basic Information And Sales Area

Table 69: Segments. Products Portfolio

Table 70: Global Market Value (USD Million) (2025-2032) By Application

Table 71: Global Market Share (%) By Application (2032)

Table 72: Global Market Value (USD Million) (2025-2032) By Types

Table 73: Global Market Share (%) By Types (2032)

Table 74: Global Alpha- Antitrypsin Deficiency Treatment Market Value (USD Million) By Region

Table 75: Global Alpha- Antitrypsin Deficiency Treatment Market Share (%) By Region (2025-2032)

Table 76: North America Market Value (USD Million) (2025-2032) By Country

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: North America Market Value (USD Million) (2025-2032) By Types

Table 79: Europe Market Value (USD Million) (2025-2032) By Country

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Europe Market Value (USD Million) (2025-2032) By Types

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 85: South America Market Value (USD Million) (2025-2032) By Country

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: South America Market Value (USD Million) (2025-2032) By Types

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 91: Research Programs/Design For This Report

Table 92: Key Data Information From Secondary Sources

Table 93: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Alpha- Antitrypsin Deficiency Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	500.00 million
Revenue forecast in 2033	1.26 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Adverum Biotechnologies, Inc.; Alnylam Pharmaceuticals, Inc.; Applied Genetic Technologies Corporation; Arrowhead Pharmaceuticals, Inc.; Carolus Therapeutics, Inc.; Cevec Pharmaceuticals GmbH; Dicerna Pharmaceuticals, Inc.; Digna Biotech, S.L.; Editas Medicine, Inc.; Grifols, S.A.; Inhibrx; Intellia Therapeutics, Inc.; International Stem Cell Corporation; Ionis Pharmaceuticals, Inc.; Kamada Ltd.; Polyphor Ltd.; ProMetic Life Sciences Inc.; rEVO Biologics, Inc.; Sangamo BioSciences, Inc.; Segments
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Alpha- Antitrypsin Deficiency Treatment Segmentation Breakdown10 items

Application

Clinic

Hospital

Others

Types

CT-2009

POL-6014

ARO-AAT

ALNAAT-02

Others

Regional Insights

Loading chart…

Key Drivers by Region5 items

North America: High adoption of personalized treatment protocols, strong reimbursement policies, and a mature healthcare ecosystem.

Europe: Stringent regulatory frameworks ensuring treatment accessibility, coupled with high patient awareness and cross-border collaborations.

Asia Pacific: Rapid urbanization, growing middle-class demographics, and government investments in healthcare infrastructure.

Latin America: Increasing partnerships with global pharmaceutical firms and expanding insurance coverage for rare diseases.

Middle East & Africa: Rising investments in diagnostic capabilities and public-private partnerships to address unmet medical needs.

Competitive Landscape

Alnylam Pharmaceuticals, Inc.: RNAi therapeutics pipeline targeting under-addressed genetic pathways

Grifols, S.A.: Expansion of plasma-derived therapy production to meet growing demand in Asia-Pacific

Adverum Biotechnologies, Inc.: AAV gene therapy development with focus on durable treatment effects

Arrowhead Pharmaceuticals, Inc.: RNAi platforms targeting transthyretin (TTR) and other rare disease proteins

Editas Medicine, Inc.: Preclinical CRISPR-Cas9 gene-editing programs for one-time curative potential

Ionis Pharmaceuticals, Inc.: Antisense oligonucleotide collaborations to expand therapeutic applications

Key Alpha- Antitrypsin Deficiency Treatment Companies20 items

Adverum Biotechnologies, Inc.

Alnylam Pharmaceuticals, Inc.

Applied Genetic Technologies Corporation

Arrowhead Pharmaceuticals, Inc.

Carolus Therapeutics, Inc.

Cevec Pharmaceuticals GmbH

Dicerna Pharmaceuticals, Inc.

Digna Biotech, S.L.

Editas Medicine, Inc.

Grifols, S.A.

Inhibrx

Intellia Therapeutics, Inc.

International Stem Cell Corporation

Ionis Pharmaceuticals, Inc.

Kamada Ltd.

Polyphor Ltd.

ProMetic Life Sciences Inc.

rEVO Biologics, Inc.

Sangamo BioSciences, Inc.

Segments

Market Ecosystem

Biologics manufacturers – Develop and commercialize alpha-1 antitrypsin replacement therapies

Plasma fractionation suppliers – Provide raw plasma for AAT purification processes

R&D technology providers – Innovate purification and gene therapy platforms for AAT production

Contract manufacturers (CMOs) – Execute large-scale production of AAT biologics

Healthcare providers – Administer treatments and manage patient care pathways

Regulatory bodies – Oversee drug approvals and compliance standards (e.g., FDA, EMA)

Reimbursement agencies – Influence treatment accessibility via coverage and pricing decisions

Recent Industry Insights

Analyst Overview

Key Insights5 items

Competitive intensity is moderate, with established players like CSL Behring dominating but emerging biotechs gaining traction via novel therapies.

Long-term outlook is optimistic, underpinned by R&D investments in precision medicine and expanding global access initiatives.

Innovation landscape is dynamic, with advancements in RNA interference and AAV-based gene therapies addressing current treatment gaps.

Demand-supply balance faces pressure due to manufacturing complexities, creating opportunities for players optimizing scalable production.

Key risk factors include regulatory uncertainties, high R&D attrition rates, and reimbursement challenges in emerging markets.

Table of Contents